Literature DB >> 25548381

Deficiency in mannose-binding lectin-associated serine protease-2 does not increase susceptibility to Trypanosoma cruzi infection.

Carolina H Ribeiro1, Nicholas J Lynch2, Cordula M Stover2, Youssif M Ali2, Carolina Valck2, Francisca Noya-Leal2, Wilhelm J Schwaeble2, Arturo Ferreira2.   

Abstract

Trypanosoma cruzi is the causative agent of Chagas' disease, a chronic illness affecting 10 million people around the world. The complement system plays an important role in fighting microbial infections. The recognition molecules of the lectin pathway of complement activation, mannose-binding lectin (MBL), ficolins, and CL-11, bind to specific carbohydrates on pathogens, triggering complement activation through MBL-associated serine protease-2 (MASP-2). Previous in vitro work showed that human MBL and ficolins contribute to T. cruzi lysis. However, MBL-deficient mice are only moderately compromised in their defense against the parasite, as they may still activate the lectin pathway through ficolins and CL-11. Here, we assessed MASP-2-deficient mice, the only presently available mouse line with total lectin pathway deficiency, for a phenotype in T. cruzi infection. Total absence of lectin pathway functional activity did not confer higher susceptibility to T. cruzi infection, suggesting that it plays a minor role in the immune response against this parasite. © The American Society of Tropical Medicine and Hygiene.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25548381      PMCID: PMC4347335          DOI: 10.4269/ajtmh.14-0236

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  41 in total

Review 1.  The lectin-complement pathway--its role in innate immunity and evolution.

Authors:  Teizo Fujita; Misao Matsushita; Yuichi Endo
Journal:  Immunol Rev       Date:  2004-04       Impact factor: 12.988

2.  The classical activation pathway of the human complement system is specifically inhibited by calreticulin from Trypanosoma cruzi.

Authors:  Viviana Ferreira; Carolina Valck; Gittith Sánchez; Alexandre Gingras; Sotiria Tzima; María Carmen Molina; Robert Sim; Wilhelm Schwaeble; Arturo Ferreira
Journal:  J Immunol       Date:  2004-03-01       Impact factor: 5.422

Review 3.  The proteolytic activation systems of complement.

Authors:  K B Reid; R R Porter
Journal:  Annu Rev Biochem       Date:  1981       Impact factor: 23.643

4.  Direct lysis of Trypanosoma cruzi: a novel effector mechanism of protection mediated by human anti-gal antibodies.

Authors:  R T Gazzinelli; M E Pereira; A Romanha; G Gazzinelli; Z Brener
Journal:  Parasite Immunol       Date:  1991-07       Impact factor: 2.280

5.  A second serine protease associated with mannan-binding lectin that activates complement.

Authors:  S Thiel; T Vorup-Jensen; C M Stover; W Schwaeble; S B Laursen; K Poulsen; A C Willis; P Eggleton; S Hansen; U Holmskov; K B Reid; J C Jensenius
Journal:  Nature       Date:  1997-04-03       Impact factor: 49.962

6.  Chagas disease: current epidemiological trends after the interruption of vectorial and transfusional transmission in the Southern Cone countries.

Authors:  Alvaro Moncayo
Journal:  Mem Inst Oswaldo Cruz       Date:  2003-09-08       Impact factor: 2.743

Review 7.  The role of mannose-binding lectin in health and disease.

Authors:  M W Turner
Journal:  Mol Immunol       Date:  2003-11       Impact factor: 4.407

8.  Resistance against Trypanosoma cruzi associated to anti-living trypomastigote antibodies.

Authors:  A U Krettli; Z Brener
Journal:  J Immunol       Date:  1982-05       Impact factor: 5.422

9.  Mannose-binding lectin-deficient mice are susceptible to infection with Staphylococcus aureus.

Authors:  Lei Shi; Kazue Takahashi; Joseph Dundee; Sarit Shahroor-Karni; Steffen Thiel; Jens Christian Jensenius; Faten Gad; Michael R Hamblin; Kedarnath N Sastry; R Alan B Ezekowitz
Journal:  J Exp Med       Date:  2004-05-17       Impact factor: 14.307

10.  Activation of the classical complement pathway by mannose-binding protein in association with a novel C1s-like serine protease.

Authors:  M Matsushita; T Fujita
Journal:  J Exp Med       Date:  1992-12-01       Impact factor: 14.307

View more
  6 in total

Review 1.  Escaping Deleterious Immune Response in Their Hosts: Lessons from Trypanosomatids.

Authors:  Anne Geiger; Géraldine Bossard; Denis Sereno; Joana Pissarra; Jean-Loup Lemesre; Philippe Vincendeau; Philippe Holzmuller
Journal:  Front Immunol       Date:  2016-05-31       Impact factor: 7.561

Review 2.  Trypanosoma cruzi Evades the Complement System as an Efficient Strategy to Survive in the Mammalian Host: The Specific Roles of Host/Parasite Molecules and Trypanosoma cruzi Calreticulin.

Authors:  Galia Ramírez-Toloza; Arturo Ferreira
Journal:  Front Microbiol       Date:  2017-09-01       Impact factor: 5.640

Review 3.  The Unsolved Jigsaw Puzzle of the Immune Response in Chagas Disease.

Authors:  Gonzalo R Acevedo; Magalí C Girard; Karina A Gómez
Journal:  Front Immunol       Date:  2018-08-24       Impact factor: 7.561

Review 4.  MBL-associated serine proteases (MASPs) and infectious diseases.

Authors:  Marcia H Beltrame; Angelica B W Boldt; Sandra J Catarino; Hellen C Mendes; Stefanie E Boschmann; Isabela Goeldner; Iara Messias-Reason
Journal:  Mol Immunol       Date:  2015-04-08       Impact factor: 4.407

Review 5.  Is It Possible to Intervene in the Capacity of Trypanosoma cruzi to Elicit and Evade the Complement System?

Authors:  Galia Ramírez-Toloza; Lorena Aguilar-Guzmán; Carolina Valck; Smrithi S Menon; Viviana P Ferreira; Arturo Ferreira
Journal:  Front Immunol       Date:  2021-12-16       Impact factor: 7.561

6.  Immunothrombotic dysregulation in chagas disease and COVID-19: a comparative study of anticoagulation.

Authors:  Laura Pérez-Campos Mayoral; María Teresa Hernández-Huerta; Dulce Papy-García; Denis Barritault; Edgar Zenteno; Luis Manuel Sánchez Navarro; Eduardo Pérez-Campos Mayoral; Carlos Alberto Matias Cervantes; Margarito Martínez Cruz; Gabriel Mayoral Andrade; Malaquías López Cervantes; Gabriela Vázquez Martínez; Claudia López Sánchez; Socorro Pina Canseco; Ruth Martínez Cruz; Eduardo Pérez-Campos
Journal:  Mol Cell Biochem       Date:  2021-06-10       Impact factor: 3.396

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.